AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18580512 — intervention group
Group type: EXPERIMENTAL
Intervention: Paco2 (IRMA)
Number of subjects: 34
Study 18580512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ptcco2
Number of subjects: 34
Study 18580512 — intervention group
Group type: EXPERIMENTAL
Intervention: Petco2
Number of subjects: 34
Study 18580512 — intervention group
Group type: COMPARATOR
Intervention: Paco2 (ABL625)
Number of subjects: 34
Study 16647383 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulase (recombinant human-derived hyaluronidase)
Number of subjects: 0
Study 16647383 — intervention group
Group type: COMPARATOR
Intervention: Hyase (bovine-derived hyaluronidase)
Number of subjects: 0
Study 12803585 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative recombinant human erythropoietin treatment (EPO group)
Number of subjects: 38
Study 12803585 — intervention group
Group type: COMPARATOR
Intervention: Autologous blood transfusion (control group)
Number of subjects: 38
Study 10816223 — intervention group
Group type: EXPERIMENTAL
Intervention: Local administration of immunoglobulin G (IgG) intranasally daily for 6 months
Number of subjects: 50
Study 10816223 — intervention group
Group type: COMPARATOR
Intervention: Placebo intranasally daily for 6 months
Number of subjects: 50
Study 10816223 — intervention group
Group type: EXPERIMENTAL
Intervention: Local administration of immunoglobulin G (IgG)
Number of subjects: 50
Study 10816223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8866410 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuEPO treatment for 1 year (Group A)
Number of subjects: 40
Study 8866410 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuEPO treatment for 2 years (Group B)
Number of subjects: 40
Study 8866410 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuEPO treatment (both groups)
Number of subjects: 40
Study 1641231 — intervention group
Group type: COMPARATOR
Intervention: Monovision (MV)
Number of subjects: 15
Study 1641231 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft diffractive (DIFF) bifocal contact lens
Number of subjects: 15
Study 1641231 — intervention group
Group type: EXPERIMENTAL
Intervention: Near center (CN) concentric bifocal design
Number of subjects: 15
Study 6826412 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside (NTP) at 20.8 micrograms/min
Number of subjects: 12
Study 6826412 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside (NTP) at 52.1 micrograms/min
Number of subjects: 12
Study 6826412 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 12
Study 6826412 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside (NTP)
Number of subjects: 12
Study 30526539 — intervention group
Group type: EXPERIMENTAL
Intervention: Branded pack without HWL
Number of subjects: 656
Study 30526539 — intervention group
Group type: COMPARATOR
Intervention: Plain pack with HWL
Number of subjects: 656
Study 30526539 — intervention group
Group type: COMPARATOR
Intervention: Branded pack with HWL
Number of subjects: 656
Study 30526539 — intervention group
Group type: COMPARATOR
Intervention: Plain pack (uniform color, brand imagery removed, standardized font)
Number of subjects: 656
Study 30526539 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warnings (5 text-based HWLs)
Number of subjects: 656
Study 27449066 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Response Resiliency Program for neurofibromatosis (3RP‐NF)
Number of subjects: 63
Study 27449066 — intervention group
Group type: COMPARATOR
Intervention: Health Enhancement Program for NF (HEP‐NF)
Number of subjects: 63
Study 23967878 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 0
Study 23967878 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 0
Study 23967878 — intervention group
Group type: COMPARATOR
Intervention: Adaptive Pacing Therapy (APT)
Number of subjects: 0
Study 23967878 — intervention group
Group type: COMPARATOR
Intervention: Specialist Medical Care (SMC)
Number of subjects: 0
Study 22308558 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional orthosis Neuro‐Lux (Sporlastic, Nürtingen, Germany) on top of usual care (n = 20)
Number of subjects: 41
Study 22308558 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (n = 21)
Number of subjects: 41
Study 22308558 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional orthosis usage
Number of subjects: 41
Study 22308558 — intervention group
Group type: EXPERIMENTAL
Intervention: Discomfort from orthosis
Number of subjects: 41
Study 20731875 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer treatment pathways and diagnostic patterns
Number of subjects: 1064
Study 20731875 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life and psychological adjustment assessments
Number of subjects: 1064
Study 18414712 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cannabinoid-containing medications (OCs)
Number of subjects: 191
Study 18414712 — intervention group
Group type: COMPARATOR
Intervention: No intervention (nonrecipients)
Number of subjects: 191
Study 15948779 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral buckling
Number of subjects: 50
Study 15948779 — intervention group
Group type: COMPARATOR
Intervention: Pars plana vitrectomy without buckling
Number of subjects: 50
Study 12597947 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg/day
Number of subjects: 43
Study 11055145 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal orientation with task difficulty
Number of subjects: 388
Study 11055145 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal orientation with task consistency
Number of subjects: 388
Study 8968305 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 40
Study 8968305 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 40
Study 1453408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid 500mg 3 times a day
Number of subjects: 160
Study 1453408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 4096214 — intervention group
Group type: EXPERIMENTAL
Intervention: Meibomian oils expressed onto the lid margins
Number of subjects: 12
Study 4096214 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthesia
Number of subjects: 12
Study 30475942 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic irradiation to the contralateral breast
Number of subjects: 162
Study 30475942 — intervention group
Group type: COMPARATOR
Intervention: Standard loco‐regional treatment including surgery and radiation to the involved side
Number of subjects: 162
Study 30521699 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial risk factor intervention
Number of subjects: 345
Study 30521699 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment according to national guidance
Number of subjects: 345
Study 26991387 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cranioplasty
Number of subjects: 64
Study 26991387 — intervention group
Group type: COMPARATOR
Intervention: Titanium cranioplasty
Number of subjects: 64
Study 25919474 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab (10 mg intravenous injection)
Number of subjects: 59
Study 25919474 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab (4 infusions of 10 mg at 8-week intervals)
Number of subjects: 59
Study 25919474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 23682163 — intervention group
Group type: EXPERIMENTAL
Intervention: Low counts of early angiogenic CPCs (CD34(+), CD34(+)CD133(+), ALDH-bright)
Number of subjects: 129
Study 22017936 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 6785
Study 22017936 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 6785
Study 19343062 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifendate (three times daily for 14 days)
Number of subjects: 18
Study 16362474 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic vascular staplers and disposable clip appliers (S/C)
Number of subjects: 100
Study 16362474 — intervention group
Group type: COMPARATOR
Intervention: LigaSure Atlas (LIG)
Number of subjects: 100
Study 15325876 — intervention group
Group type: EXPERIMENTAL
Intervention: TSP/HEPA cleaning method (high-efficiency particulate air vacuum cleaner and tri-sodium phosphate solution)
Number of subjects: 40
Study 15325876 — intervention group
Group type: COMPARATOR
Intervention: Non-TSP/non-HEPA cleaning method (household vacuum cleaner and household detergent)
Number of subjects: 40
Study 15325876 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (TSP/HEPA and non-TSP/non-HEPA)
Number of subjects: 40
Study 15325876 — intervention group
Group type: EXPERIMENTAL
Intervention: TSP/HEPA method
Number of subjects: 40
Study 15325876 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-TSP/non-HEPA method
Number of subjects: 40
Study 15325876 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 40
Study 11174679 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular implant-supported overdenture (IOD)
Number of subjects: 89
Study 11174679 — intervention group
Group type: COMPARATOR
Intervention: Conventional complete mandibular denture (CD)
Number of subjects: 89
Study 9436823 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol (200 mg)
Number of subjects: 12
Study 9436823 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol (800 mg)
Number of subjects: 12
Study 9436823 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol (160 mg)
Number of subjects: 12
Study 9436823 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol (50 mg)
Number of subjects: 12
Study 9436823 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol (200 mg and 800 mg) with atenolol
Number of subjects: 12
Study 9436823 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 12
Study 9436823 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol
Number of subjects: 12
Study 9436823 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 12
Study 9436823 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol and atenolol
Number of subjects: 12
Study 8493730 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilchrist bandage
Number of subjects: 28
Study 8493730 — intervention group
Group type: COMPARATOR
Intervention: Desault bandage
Number of subjects: 28
Study 3431825 — intervention group
Group type: EXPERIMENTAL
Intervention: +1.00‐D overcorrection
Number of subjects: 5
Study 3431825 — intervention group
Group type: EXPERIMENTAL
Intervention: +2.00‐D overcorrection
Number of subjects: 5
Study 3431825 — intervention group
Group type: EXPERIMENTAL
Intervention: +3.00‐D overcorrection
Number of subjects: 5
Study 3431825 — intervention group
Group type: EXPERIMENTAL
Intervention: +4.00‐D overcorrection
Number of subjects: 5
Study 3431825 — intervention group
Group type: EXPERIMENTAL
Intervention: +5.00‐D overcorrection
Number of subjects: 5
Study 3431825 — intervention group
Group type: EXPERIMENTAL
Intervention: +6.00‐D overcorrection
Number of subjects: 5
Study 3431825 — intervention group
Group type: COMPARATOR
Intervention: plano overcorrection
Number of subjects: 5
Study 28870848 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 45
Study 27470233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (bolus + 48-hr infusion)
Number of subjects: 202
Study 27470233 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical infusion volume and duration)
Number of subjects: 202
Study 24552852 — intervention group
Group type: EXPERIMENTAL
Intervention: Online hemodiafiltration
Number of subjects: 405
Study 24552852 — intervention group
Group type: COMPARATOR
Intervention: Low-flux hemodialysis
Number of subjects: 405
Study 24552852 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 405
Study 23312829 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg per day
Number of subjects: 118
Study 23312829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 23312829 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 118
Study 20826832 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity intervention (mail contact)
Number of subjects: 500
Study 20826832 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervention (mail plus telephone or personal contact)
Number of subjects: 500
Study 20826832 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 500
Study 18612159 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoma presence at first colonoscopy
Number of subjects: 695
Study 18612159 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperplastic polyp presence at first colonoscopy
Number of subjects: 695
Study 18612159 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoma prevalence by age
Number of subjects: 695
Study 18612159 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurrence of adenomas and hyperplastic polyps
Number of subjects: 695
Study 18612159 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution of adenomas and hyperplastic polyps
Number of subjects: 695
Study 16857655 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein
Number of subjects: 0
Study 16857655 — intervention group
Group type: EXPERIMENTAL
Intervention: Red clover isoflavones
Number of subjects: 0
Study 16857655 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone products
Number of subjects: 0
Study 16857655 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones from soy and red clover
Number of subjects: 0
Study 14521495 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 0
Study 14521495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11189975 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser irradiation at 1 W and 15 pps for 1 second in 23 teeth (laser-treated group)
Number of subjects: 29
Study 11189975 — intervention group
Group type: COMPARATOR
Intervention: Control group treated without laser irradiation
Number of subjects: 29
Study 8673750 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt supplement (120 mmol/day of sodium chloride)
Number of subjects: 31
Study 8673750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 1496946 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron therapy (syrup containing iron, daily for 2 months)
Number of subjects: 59
Study 1496946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 7046781 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline
Number of subjects: 12
Study 7046781 — intervention group
Group type: COMPARATOR
Intervention: Oral terbutaline
Number of subjects: 12
Study 31648006 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 35
Study 31648006 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Training (PT)
Number of subjects: 35
Study 31648006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ST and PT
Number of subjects: 35
Study 28894068 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-warming for 30 minutes
Number of subjects: 62
Study 28894068 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pre-warming)
Number of subjects: 62
Study 27346964 — intervention group
Group type: EXPERIMENTAL
Intervention: Transport of samples to the laboratory
Number of subjects: 1505
Study 27346964 — intervention group
Group type: EXPERIMENTAL
Intervention: Labelling of samples
Number of subjects: 1505
Study 27346964 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF chemistry requests without appropriate number of CSF sample tubes
Number of subjects: 1505
Study 24393146 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthen your ankle App
Number of subjects: 0
Study 24393146 — intervention group
Group type: COMPARATOR
Intervention: Traditional instructional booklet
Number of subjects: 0
Study 19131285 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy
Number of subjects: 0
Study 15645098 — intervention group
Group type: EXPERIMENTAL
Intervention: Octopirox at 0.2% active delivered in the amphiphile blend
Number of subjects: 30
Study 15645098 — intervention group
Group type: COMPARATOR
Intervention: Octopirox at 0.5% in the simple shampoo base
Number of subjects: 30
Study 11691705 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (5 to 200 mg/day)
Number of subjects: 98
Study 11691705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 9137191 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ultrasound device
Number of subjects: 0
Study 7956700 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor infiltrating lymphocytes (TILs) immunotherapy
Number of subjects: 10
Study 7956700 — intervention group
Group type: COMPARATOR
Intervention: Lymphokine activated killer (LAK) cell therapy
Number of subjects: 10
Study 3604620 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-viscosity cement
Number of subjects: 16
Study 3604620 — intervention group
Group type: COMPARATOR
Intervention: High-viscosity cement
Number of subjects: 16
Study 11448083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.8 g/kg up to a maximum of 60 g for males, 50 g for females)
Number of subjects: 47
Study 11448083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 11448083 — intervention group
Group type: EXPERIMENTAL
Intervention: Pen computer (PenC) battery
Number of subjects: 47
Study 11448083 — intervention group
Group type: COMPARATOR
Intervention: Pencil-and-paper (PP) tests
Number of subjects: 47
Study 11448083 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scales (VAS)
Number of subjects: 47
Study 31366522 — intervention group
Group type: EXPERIMENTAL
Intervention: Various antiemetics (ADs) combinations
Number of subjects: 180
Study 29415060 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based fat and muscle quantification
Number of subjects: 36
Study 26606381 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (40 mg/m² twice a day for 28 consecutive days, repeated every 6 weeks)
Number of subjects: 32
Study 26606381 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 32
Study 24849450 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg loading dose and 0.5 µg·kg(‐1)·h(‐1) maintenance dose
Number of subjects: 80
Study 24849450 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.8 µg·kg(‐1)·h(‐1) maintenance dose
Number of subjects: 80
Study 24849450 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.2 µg/kg loading dose and 0.2 µg·kg(‐1)·h(‐1) maintenance dose
Number of subjects: 80
Study 24849450 — intervention group
Group type: COMPARATOR
Intervention: Control group without dexmedetomidine
Number of subjects: 80
Study 24849450 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D3 (0.8 µg/kg loading dose and 0.8 µg·kg(‐1)·h(‐1) maintenance dose
Number of subjects: 80
Study 22929629 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg intravaginal Misoprostol
Number of subjects: 200
Study 22929629 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg intracervical Dinoprostone
Number of subjects: 200
Study 20089970 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies (CDA1 and CDB1) at a dose of 10 mg/kg
Number of subjects: 200
Study 20089970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 17292481 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 33
Study 17292481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 17292481 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (rescue arm)
Number of subjects: 33
Study 17292481 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine and Placebo
Number of subjects: 33
Study 16202539 — intervention group
Group type: EXPERIMENTAL
Intervention: Family intervention
Number of subjects: 232
Study 16202539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention
Number of subjects: 232
Study 16202539 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 232
Study 12117044 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol Diskus (50 microg)
Number of subjects: 15
Study 12117044 — intervention group
Group type: COMPARATOR
Intervention: placebo Diskus
Number of subjects: 15
Study 10354248 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of patients with cataract attending a peripheral ophthalmic clinic for day-surgery
Number of subjects: 0
Study 7669489 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) 200 mg m‐2
Number of subjects: 0
Study 7669489 — intervention group
Group type: EXPERIMENTAL
Intervention: Dideoxyinosine (ddI) 100 mg m‐2
Number of subjects: 0
Study 7669489 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ZDV 200 mg m‐2 plus ddI 100 mg m‐2
Number of subjects: 0
Study 1701541 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitoring
Number of subjects: 15
Study 1701541 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed electrical stimulation (PES)
Number of subjects: 15
Study 1701541 — intervention group
Group type: COMPARATOR
Intervention: Exercise testing
Number of subjects: 15
Study 7379451 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (50 gm as a water suspension followed by 4 doses of 17 gm at 12-hr intervals)
Number of subjects: 7
Study 7379451 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (80 gm/day for 1 or 2 days)
Number of subjects: 7
Study 7379451 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 7
Study 31411383 — intervention group
Group type: EXPERIMENTAL
Intervention: Orodispersible minitablet (ODMT) 10 x 1 mg dispersed on the tongue
Number of subjects: 24
Study 31411383 — intervention group
Group type: EXPERIMENTAL
Intervention: Orodispersible minitablet (ODMT) 10 x 1 mg swallowed with water
Number of subjects: 24
Study 31411383 — intervention group
Group type: COMPARATOR
Intervention: Reference product (RP) Renitec, 2 x 5 mg tablets swallowed with water
Number of subjects: 24